Administrative Core

行政核心

基本信息

批准号：
8437240
负责人：
PHILIP Frederick SPARLING
金额：
$ 48.25万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8437240
关键词：
Academia Alabama Alphavirus Animal Model Antibodies Antiviral Agents Area Bacillus anthracis spore Bacteriology Binding Biology Breathing Categories Chikungunya virus Clinical Clostridium Collaborations Commit Communicable Diseases Complement Coronavirus Dengue Dengue Virus Development Disease Drops Emergency Situation Emerging Communicable Diseases Encephalitis Viruses Environment Epitopes Extreme drug resistant tuberculosis Flavivirus Florida Foundations Francisella tularensis Funding Germination Goals Gram-Positive Bacteria Health Immune Immune response Immune system Immunology Immunosuppression Individual Infection Infectious Agent Institution Intervention Lead Ligands Lung Mission Modeling Multidrug-Resistant Tuberculosis Mutation Natural Immunity Nature North Carolina Pathogenesis Pathway interactions Pharmaceutical Preparations Plague Poxviridae Prevention Private Enterprises Proteins Public Health Reagent Reproduction spores Research Research Personnel Research Training Risk Role Route Science Scientist Structure Sum Testing Translating Tropism Tularemia Universities Vaccines Viral Virulence Virus West Nile virus Work Zoonoses base biodefense disorder risk drug development drug discovery effective therapy experience human disease influenzavirus interest member mouse model multidisciplinary novel novel vaccines pathogen pathogenic bacteria programs public-private partnership receptor response screening structural biology vaccine development virology virus pathogenesis

项目摘要

We are proud to present the SERCEB (Southeast Regional Center of Excellence for Emerging Infections and Biodefense) plan for the next five years of research, training and emergency response. Our organizing theme is "host-pathogen interactions: opportunities for intervention." We bring together an integrated and experienced team of superb investigators in virology, bacteriology, immunology, drug discovery and vaccine development whose ability to work together has been clearly demonstrated in the past five years. We believe our group is second to none, and look forward to the challenges and opportunities ahead with great confidence in our ability to deliver the highest quality discovery science, and in our ability to deliver clinically useful products. We work together in synergistic teams that span boundaries between universities, between basic scientists and public health workers,.and between academia and private enterprise. We are stronger by far than the sum of our individual parts. Our focus is in areas where our particular strengths add to or complement those of our partners throughout the national Regional Centers of Excellence (RCE) program. SERCEB is multidisciplinary team based in Region IV. The Prime Institution is the University of North Carolina Chapel Hill (UNC), and the other principal consortium members include Duke University, Emory University, Vanderbilt University, the University of Florida (Gainesville), and the University of Alabama at Birmingham. Our primary goal is to assist the nation in developing and deploying effective and rapid responses to biodefense and emerging infectious diseases threats. To this end, we will discover new therapies and principles by which effective new vaccines can be developed. Our pathways to discovery include better understanding of the pathogenic mechanisms by which pathogens cause disease and the nature of the immune responses against them. Hence, mechanistic studies on pathogenesis and animal models will also be a focus of study. We will concentrate on areas that offer promise for discovery of broad targets for therapy or prevention. We emphasize pathogen interactions with the innate immune system, an area of great SERCEB strength that offers excellent opportunities for discovery of broadly effective therapies. Discovery of new therapies also includes a focused screening and drug development team effort, which although not directly derived from studies of basic pathogenesis, depends in part on studies of pathogenesis to validate targets. Vaccine discovery is based on identification of crucial shared protective epitopes and protective, as opposed to deleterious, immune responses.

我们很自豪地介绍SERCEB（东南地区新兴感染卓越中心和 Biodefense）未来五年的研究，培训和应急响应的计划。我们的组织主题是“宿主 - 病原体相互作用：干预的机会”。我们汇集了一个综合的经验丰富的流行病学，细菌学，免疫学，药物发现和疫苗的精湛研究者团队在过去的五年中，清楚地证明了其共同努力的发展。我们相信我们的小组首屈一指，并期待着未来的挑战和机遇为了提供最高质量的发现科学的能力，并能够提供临床上有用的能力产品。我们在跨越大学之间边界的协同团队中一起工作科学家和公共卫生工作者，学术界和私营企业之间。到目前为止，我们更强大比我们各个部分的总和。我们的重点是我们的特定优势增加或补充的领域我们的合作伙伴遍布全国卓越区域中心（RCE）计划。 SERCEB是基于IV区域的多学科团队。主要机构是北卡罗来纳大学教堂山（UNC）和其他主要财团成员包括杜克大学，埃默里大学，范德比尔特大学，佛罗里达大学（盖恩斯维尔）和伯明翰的阿拉巴马大学。我们的主要目标是协助国家开发和部署有效和快速的响应生物形式和新兴的传染病威胁。为此，我们将发现新的疗法和可以开发有效的新疫苗的原则。我们的发现途径包括更好了解病原体引起疾病和性质的病原机制对他们的免疫反应。因此，关于发病机理和动物模型的机械研究将也是研究的重点。我们将专注于为发现广泛目标提供希望的领域用于治疗或预防。我们强调与先天免疫系统的病原体相互作用，一个区域伟大的SERCEB力量为发现广泛有效的疗法提供了绝佳的机会。新疗法的发现还包括一项重点的筛查和药物开发团队的工作，这是尽管不是直接来自基本发病机理的研究，但部分取决于发病机理的研究验证目标。疫苗发现基于对关键共享保护表位的识别和保护性，而不是有害的免疫反应。